Business Context and Reporting Period
This Form 6-K filing by Apollomics Inc. covers the month of September 2025, specifically reporting on events occurring on September 2 and September 3, 2025. The filing details the closing of a private placement (PIPE), significant changes to the Board of Directors, and the cancellation of a scheduled extraordinary general meeting.
Key Financial Metrics
- Capital Raised: The Company raised aggregate gross proceeds of $4.1 million prior to fees and expenses.
- Shares Issued: 1.04 million Class A ordinary shares were issued to accredited investors.
- Price Per Share: Shares were sold at $3.9317, based on the closing price on August 29, 2025.
- Ownership Structure: Following the issuance, Hung-Wen (Howard) Chen and affiliates beneficially own approximately 42% of outstanding Class A ordinary shares. Maxpro Investment Co., Ltd. and affiliates own approximately 7%.
- Other Metrics: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Board Composition: The Board underwent a complete overhaul. Dr. Kenneth C. Carter, Wendy Hayes, Dr. Sanjeev Redkar, Glenn S. Vraniak, and Dr. Bob Lin resigned. They were replaced by Howard Chen (appointed Chairman), Yi-Kuei Chen, Po-Jen Hsueh, and Hsien-Chu Tsai. Moses Chen remains on the Board.
- Employee Status: The filing notes the previously announced termination of all U.S. employees, including Dr. Guo-Liang Yu.
- Corporate Actions: The proposed extraordinary general meeting of members scheduled for September 4, 2025, was cancelled following the successful PIPE funding.
Outlook, Risks, and Management Commentary
- Management Background: New directors bring experience in biotechnology, venture capital, and corporate restructuring. Howard Chen previously led a turnaround at Polaris Pharmaceuticals. Yi-Kuei Chen has executed over 60 private equity transactions. Po-Jen Hsueh and Hsien-Shu Tsai have extensive backgrounds in finance and operations within the biopharmaceutical and technology sectors.
- Registration Obligations: The Company must file a registration statement with the SEC within 30 days of the Closing Date to register the resale of PIPE shares.
- Risks and Contingencies: The securities were sold under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. They may not be offered or sold in the U.S. absent registration or an applicable exemption.
Investor Verification Checklist
- Verify the final net proceeds after deducting fees and expenses from the $4.1 million gross amount.
- Confirm the current cash runway and liquidity position following the termination of all U.S. employees.
- Review the specific terms of the PIPE Subscription Agreement (Exhibit 10.1) for any restrictive covenants or liquidation preferences.
- Monitor the filing of the required resale registration statement within the 30-day window.
- Assess the strategic plan of the new management team given the significant reduction in operational footprint.